

Ref: FOI/GS/ID 7488

**Please reply to:**  
FOI Administrator  
Trust Management  
Maidstone Hospital  
Hermitage Lane  
Maidstone, Kent  
ME16 9QQ  
Email: [mtw-tr.foiadmin@nhs.net](mailto:mtw-tr.foiadmin@nhs.net)  
[www.mtw.nhs.uk](http://www.mtw.nhs.uk)

27 June 2022

## **Freedom of Information Act 2000**

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to Lung cancer.

*You asked:*

*Q1. In the past 3 months, how many non-small cell lung cancer (NSCLC) patients were treated with:*

- a. Afatinib*
- b. Alectinib*
- c. Amivantamab*
- d. Atezolizumab monotherapy*
- e. Atezolizumab with chemotherapy*
- f. Brigatinib*
- g. Ceritinib*
- h. Crizotinib*
- i. Dacomitinib*
- j. Dabrafenib with Trametinib*
- k. Durvalumab*
- l. Erlotinib*
- m. Gefitinib*
- n. Lorlatinib*
- o. Mobocertinib*
- p. Nintedanib with Docetaxel*
- q. Nivolumab*
- r. Osimertinib*
- s. Pembrolizumab monotherapy*
- t. Pembrolizumab with chemotherapy*
- u. Pemetrexed with Carboplatin/Cisplatin*
- v. Sotorasib*
- w. Tepotinib*
- x. Vinorelbine with Carboplatin/Cisplatin*

- y. *Any other active systemic anti-cancer therapy (SACT)*
  - z. *Palliative care only*
- Q2. *In the past 3 months, how many patients were treated for Squamous non-small cell lung cancer (Sq NSCLC) ONLY with the following drugs:*
- a. *Atezolizumab monotherapy*
  - b. *Atezolizumab with chemotherapy*
  - c. *Durvalumab*
  - d. *Nivolumab*
  - e. *Osimertinib*
  - f. *Pembrolizumab (Keytruda) Mono*
  - g. *Pembrolizumab (Keytruda) with Chemotherapy*
  - h. *Tepotinib*
  - i. *Other active systemic anti-cancer therapy (SACT)*
  - j. *Palliative care only*

Trust response:

Q1.

- a. 2
  - b. 5
  - c. 0
  - d. 2
  - e. 0
  - f. 1
  - g. 0
  - h. 2
  - i. 0
  - j. 0
  - k. 4
  - l. 0
  - m. 1
  - n. 1
  - o. 0
  - p. 0
  - q. 0
  - r. 18
  - s. 23
  - t. 17
  - u. 4
  - v. 2
  - w. 0
  - x. 10
  - y. 10
  - z. 0
- Q2.
- a. 1
  - b. 0
  - c. 0
  - d. 0
  - e. 1
  - f. 5

g. 0  
h. 0  
i. 7  
j. 0